Outlook Therapeutics, Inc. - 8-K Filing
Outlook Therapeutics announced that the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA™, an ophthalmic formulation of bevacizumab intended to treat wet AMD. The BLA is classified as a Class 1 review with a PDUFA goal date set for July 29, 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $OTLK